BRIEF – OMass Therapeutics raises £14 million in series A round
Oxford, UK-based OMass Therapeutics has raised £14 million ($18 million) in a series A financing round, led by Syncona, alongside Oxford Sciences Innovation (OSI)…
MORERelated News
Native mass spectrometry: Drug discovery’s new kid on the block
July 26, 2022
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s...
Novel drug-discovery approach lands big backers
May 5, 2022
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
April 29, 2022
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...